Multiple endocrine neoplasia: an update.


Journal

Internal medicine journal
ISSN: 1445-5994
Titre abrégé: Intern Med J
Pays: Australia
ID NLM: 101092952

Informations de publication

Date de publication:
08 2019
Historique:
received: 04 04 2019
revised: 22 05 2019
accepted: 29 05 2019
entrez: 7 8 2019
pubmed: 7 8 2019
medline: 10 4 2020
Statut: ppublish

Résumé

The multiple endocrine neoplasia (MEN) syndromes include MEN1, MEN2 (formerly MEN2A), MEN3 (formerly MEN2B) and the recently identified MEN4. Clinical presentations are varied and often relate to the overproduction of specific hormones. Understanding the genetics of each syndrome assists in determining screening timelines. Treatments for each manifestation are dependent on location, risk of recurrence or malignancy, hormone excess and surgical morbidity. Multidisciplinary management should include geneticists, genetic counsellors, endocrinologists and endocrine surgeons.

Identifiants

pubmed: 31387156
doi: 10.1111/imj.14394
doi:

Substances chimiques

Genetic Markers 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

954-961

Informations de copyright

© 2019 Royal Australasian College of Physicians.

Auteurs

Jane E McDonnell (JE)

Department of Endocrinology and Diabetes, Royal North Shore Hospital, Sydney, New South Wales, Australia.

Matti L Gild (ML)

Department of Endocrinology and Diabetes, Royal North Shore Hospital, Sydney, New South Wales, Australia.
Cancer Genetics Unit, Kolling Institute, Sydney, New South Wales, Australia.
Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.

Roderick J Clifton-Bligh (RJ)

Department of Endocrinology and Diabetes, Royal North Shore Hospital, Sydney, New South Wales, Australia.
Cancer Genetics Unit, Kolling Institute, Sydney, New South Wales, Australia.
Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.

Bruce G Robinson (BG)

Department of Endocrinology and Diabetes, Royal North Shore Hospital, Sydney, New South Wales, Australia.
Cancer Genetics Unit, Kolling Institute, Sydney, New South Wales, Australia.
Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH